Vitalograph’s vision for the future of respiratory diagnostics: an interview with Gareth Morgan

Gareth Morgan, Executive Vice President of Vitalograph US, discusses the company’s vision for the future of respiratory diagnostics in a new interview with Respiratory Therapy.

Built on strong foundations

Vitalograph’s US business has grown fast since 2024. Yearly US sales of its pulmonary function testing (PFT) solutions have nearly doubled, and the US team has more than doubled in size. Gareth sees this as the platform for the next chapter, with the best of both teams coming together into something greater than the sum of its parts.

Gareth credits Vitalograph’s leadership team, CEO Frank Keane, Chief Commercial Officer Gary Lancaster and Chief Science & Strategy Officer Helen Venn, with giving him the opportunity to help shape a shared view of what the business could become. It is a plan the team has been putting into action for the past two years.

Meeting customers at every stage

Gareth describes Vitalograph’s offering as a “continuum of solutions”. Vitalograph designs, develops and manufactures across the whole of respiratory diagnostics, from filters and peak flow meters to advanced PFT systems, plethysmographs and CPET equipment. Across its PFT range, Vitalograph’s comPAS2 software brings advanced PFT, spirometry and complementary diagnostics together on one configurable platform. Customers can scale up or down as their needs change, an approach Gareth says is considered unique in the industry.

Seeing both sides of respiratory care

In addition to its 60+ years in respiratory diagnostics, Vitalograph has more than 20 years of experience supporting pharmaceutical companies with respiratory clinical trials. Gareth says this gives the company an unusual view across both patient care today and the development of tomorrow’s treatments, and it shapes how Vitalograph innovates.

A very different future

Gareth believes pulmonary diagnostics will look very different within ten years, and he sees artificial intelligence as a major driver.

Gareth Morgan, Executive Vice President of Vitalograph US, said: “The increase of AI use in every industry is accelerating product development timelines.”

Alongside AI, he sees digital health moving monitoring out of the PFT lab and into patients’ homes. He compares home respiratory monitors to modern insulin pumps, which can warn patients early and share data with their doctors. Vitalograph is developing digital health technologies that extend care beyond the PFT lab and into the home, helping clinicians identify problems and intervene earlier.

Education remains a priority too. Vitalograph has expanded its learning platform, giving customers training both remotely and in person, and is the official sponsor of the AARC Pulmonary Function Test Guide.

Vitalograph also hosts the annual Future Readiness: Respiratory Diagnostics Summit in the UK, which is dedicated to advancing PFT education, discussion and innovation among the clinical community. It brings leading respiratory experts together for discussion, debate and education focused on the future of respiratory diagnostics.

For Gareth, the future is less about specific products and more about a mindset of “not sitting still”.

Read the full interview on Respiratory Therapy: Building the Future of Respiratory Diagnostics: Gareth Morgan on Vitalograph’s Next Chapter

Originally published by Respiratory Therapy, 13 November 2026.

Wie können wir Ihnen helfen?